Vertex Pharmaceuticals Incorporated
Last updated September 27, 2026
Organization details
- Legal name
- Vertex Pharmaceuticals Incorporated
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Massachusetts
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- VRTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000875320
- EIN
- 04-3039129
Board of directors
-
Alan M. Garber · DirectorSince 2023
-
Bruce I. Sachs · DirectorSince 2023
-
Diana Mckenzie · DirectorSince 2023
-
Jeffrey M. Leiden · Director · Executive ChairmanSince 2023
-
Jennifer Schneider · DirectorSince 2024
-
Lloyd Carney · DirectorSince 2023
-
Margaret G. Mcglynn · DirectorSince 2023
-
Michel Lagarde · DirectorSince 2023
-
Nancy Thornberry · DirectorSince 2023
-
Reshma Kewalramani · Director · CEO & PresidentSince 2023
-
Sangeeta N. Bhatia · DirectorSince 2023
-
Suketu Upadhyay · DirectorSince 2023
-
Terrence C. Kearney · DirectorSince 2023
-
Yuchun Lee · DirectorSince 2023
Chief executives
Reshma Kewalramani
· CEO & President
Dates unknown
Director election results
Annual meeting of May 13, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.1%
-
95.6%
-
98.4%
-
98.8%
-
98.8%
-
98.9%
-
99.3%
-
99.3%
-
99.3%
-
99.6%
Board connections
8 of this board's directors also sit on 11 other boards.
- via Nancy Thornberry
- via Alan M. Garber
- via Reshma Kewalramani
- via Lloyd Carney
- via Diana Mckenzie
- via Margaret G. Mcglynn
- via Jeffrey M. Leiden
- via Nancy Thornberry
- via Lloyd Carney
- via Michel Lagarde
- via Diana Mckenzie
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $158,378,024
- 94 sales by 13 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | van Grunsven Jasper Officer (EVP, CP and NPPO) | Grant or award | +8,682 | — | — |
| Aug 28, 2026 | Ambrose Kristen Officer (SVP & Chief Accounting Officer) | Grant or award | +5,000 | — | — |
| Aug 27, 2026 | Bruce I. Sachs Director | Gift | −6,000 | — | — |
| Jul 21, 2026 | Sachdev Amit Officer (EVP Chief Patient & Ext Af Off) | Grant or award | +8,251 | — | — |
| Jul 21, 2026 | Ourania Tatsis Officer (EVP, Chief Reg. & Quality Off.) | Grant or award | +8,251 | — | — |
| Jul 2, 2026 | McKechnie Duncan Officer (EVP, Chief Commercial Officer) | Open-market sale | −1,541 | $519.00 | $799,779 |
| Jul 2, 2026 | Ourania Tatsis Officer (EVP, Chief Reg. & Quality Off.) | Open-market sale | −1,500 | $524.99 | $787,485 |
| Jul 1, 2026 | Liu Joy Officer (EVP and Chief Legal Officer) | Open-market sale | −828 | $502.71 | $416,244 |
| Jun 26, 2026 | Bozic Carmen Officer (EVP and CMO) | Open-market sale | −596 | $482.50 | $287,570 |
| Jun 18, 2026 | Bozic Carmen Officer (EVP and CMO) | Open-market sale | −1,020 | $462.17 | $471,413 |
| Jun 15, 2026 | Bozic Carmen Officer (EVP and CMO) | Open-market sale | −4,062 | $450.00 | $1,827,900 |
| Jun 5, 2026 | Bozic Carmen Officer (EVP and CMO) | Open-market sale | −1,745 | $450.00 | $785,250 |
| Jun 1, 2026 | Liu Joy Officer (EVP and Chief Legal Officer) | Open-market sale | −828 | $439.91 | $364,245 |
| May 29, 2026 | Bozic Carmen Officer (EVP and CMO) | Open-market sale | −1,974 | $450.00 | $888,300 |
| May 15, 2026 | Bunnage Mark E. Officer (EVP, Chief Scientific Officer) | Open-market sale | −33 | $453.45 | $14,964 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.